Asunto(s)
Parasitosis Intestinales/diagnóstico , Personal Militar , Esquistosomiasis/diagnóstico , Enfermedades de la Vejiga Urinaria/parasitología , Antihelmínticos/uso terapéutico , Francia , Humanos , Parasitosis Intestinales/tratamiento farmacológico , Praziquantel/uso terapéutico , Esquistosomiasis/tratamiento farmacológico , Enfermedades de la Vejiga Urinaria/tratamiento farmacológicoRESUMEN
OBJECTIVE: Our aim was to study the lipoprotein (a) (Lp(a)) levels in various pathological states. EXPERIMENTAL DESIGN: This investigation was prospective and included a healthy control group. SETTING: This study was carried out in two internal medicine and angiology services in teaching hospitals. PATIENTS: 505 patients were included with various diseases: 66 acute infections, 9 HIV infections, 25 cancers, 86 diabetes, 36 systemic diseases, 94 atheromatous vascular disease, 27 arterial hypertensions. A control group was composed of 21 healthy subjects. INTERVENTIONS: There was no therapeutic intervention but cardiovascular treatments were recorded. MEASURES: Serum Lp(a), total cholesterol, triglycerides, HDL-cholesterol, calculated LDL-cholesterol, apolipoproteins A-I and B were measured together with inflammatory parameters, serum creatinine, proteinuria, serum aminotransferase activity. RESULTS: There was no difference in Lp(a) levels between controls and each patient group. However, a correlation was found in systemic diseases between Lp(a) and C reactive protein (r = 0.371, p = 0.026) or serum albumin concentration (r = 0.453, p = 0.006). In hypertension, Lp(a) correlated with serum creatinine (r = 0.420, p = 0.03). In the whole patient population, Lp(a) was correlated with cholesterol (r = 0.156, p = 0.0001), apolipoprotein B (r = 0.215, p = 0.0001), age (r = 0.108, p = 0.015), arterial events (r = 0.174, p = 0.0001) and platelet anti-aggregant drugs (r = 0.169, p = 0.0001). CONCLUSIONS: Lp(a), was related to atheromatous events and in systemic diseases to inflammation, suggesting that Lp(a) might vary in some patients in a manner similar to acute phase proteins.
Asunto(s)
Enfermedades Cardiovasculares/sangre , Lipoproteína(a)/sangre , Adulto , Anciano , Apolipoproteínas B/sangre , Arteriosclerosis/sangre , Arteriosclerosis/tratamiento farmacológico , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/epidemiología , Estudios de Casos y Controles , Colesterol/sangre , Diabetes Mellitus/sangre , Femenino , Infecciones por VIH/sangre , Humanos , Hipertensión/sangre , Hipertensión/tratamiento farmacológico , Infecciones/sangre , Masculino , Persona de Mediana Edad , Neoplasias/sangre , Estudios ProspectivosRESUMEN
In a six-month double-blind study in an inpatient chemical dependency facility, 29 cocaine-dependent subjects were studied to determine if the amino acids, L-tryptophan and L-tyrosine, would decrease cocaine craving and withdrawal symptoms. Those subjects receiving placebo were shown to have a statistically significant increase in only one physical symptom category. The drug craving and other major physical and subjective symptoms were not shown to be significant. This study is consistent with a literature review in demonstrating that the amino acids do not significantly reduce most symptoms of cocaine craving and withdrawal when used alone.